Halozyme Therapeutics (HALO) Earnings Date & Reports

Key Takeaways

• Total revenue reached $493 million in the third quarter of 2026, up 39% year over year and ahead of the analyst consensus estimate of roughly $487 million.
• Adjusted (non-GAAP) earnings per share came in at $2.39, topping the consensus estimate of $2.28 by $0.11.
• Royalty revenue, the company's most closely watched metric, surged 44% year over year to a record $341 million.
• Management raised its full-year 2026 guidance across revenue, adjusted earnings per share, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).
• Despite the broad beat, shares fell about 6% in after-hours trading as the raised guidance largely matched already-elevated investor expectations.
• For more context on Halozyme's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for timely analysis and data.
• You can also explore Trending AI Robots to discover AI-powered trading tools and strategies.

Earnings Context and Why It Matters

Halozyme Therapeutics derives the majority of its revenue from royalties tied to its ENHANZE drug-delivery technology, which enables the subcutaneous (under-the-skin) administration of large-molecule biologic therapies. Because the company's top line is directly linked to the commercial success of partner products such as Johnson & Johnson's DARZALEX SC, argenx's VYVGART Hytrulo, and Roche's Phesgo, each quarterly report offers investors a real-time read on the durability and diversification of those royalty streams. The third quarter of 2026 was significant because it tested whether the momentum that drove a record second quarter could be sustained, and whether management's guidance would keep pace with a stock that had already climbed sharply in 2026.

Reported Results

Halozyme reported third-quarter 2026 total revenue of $493 million, a 39% increase from $354 million in the prior-year period and slightly above the consensus estimate of approximately $487 million. Royalty revenue climbed 44% year over year to a record $341 million, driven by continued uptake of ENHANZE-enabled products including VYVGART Hytrulo, DARZALEX SC, and Phesgo.

Adjusted (non-GAAP) diluted earnings per share rose to $2.39, beating the consensus estimate of $2.28 by $0.11 and up from $1.72 in the same quarter a year earlier. GAAP (generally accepted accounting principles) diluted earnings per share was $2.01, while net income increased 41% year over year to approximately $247 million. Adjusted EBITDA reached $336.2 million, reflecting a 68.2% margin.

Management also raised its full-year 2026 outlook. The company now expects total revenue of $1.860 billion to $1.925 billion, adjusted EBITDA of $1.240 billion to $1.290 billion, and adjusted diluted earnings per share of $8.75 to $9.05.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual research. If you are looking to uncover new opportunities across sectors and strategies, the AI Screener offers a practical starting point for your analysis.

Market Reaction and Investor Sentiment

Heading into the report, investor expectations were high: Halozyme shares had surged roughly 95% year to date, reflecting confidence in the company's royalty-driven growth model. The results themselves exceeded Wall Street's estimates across revenue, earnings per share, and adjusted EBITDA, but the stock still fell approximately 6% in after-hours trading.

The decline illustrates how much of the good news was already priced in. Although management raised full-year guidance, the updated midpoint for revenue and adjusted earnings per share landed only modestly above consensus, disappointing investors who had anticipated a larger step-up. The muted response suggests the market is now looking beyond near-term royalty beats and toward proof points on newer growth engines.

Forward Outlook and Key Factors to Monitor

Halozyme enters the final stretch of 2026 with raised full-year guidance and a royalty portfolio that is broadening beyond its flagship products. The company expanded ENHANZE collaboration agreements with argenx, Incyte, and Johnson & Johnson during the quarter, and three ENHANZE programs advanced into Phase 1 clinical development, bringing total products in development to twelve.

Investors will be watching several factors in the quarters ahead. First, the trajectory of newer launched products such as OCREVUS, Opdivo, TECENTRIQ, and RYBREVANT will indicate how quickly Halozyme can offset any future royalty step-downs on more mature therapies as patents approach expiration around 2029. Second, the company's newer HyperCon and Aerocon hyperconcentration platforms represent a longer-term opportunity, with the first two HyperCon products expected to enter Phase 1 clinical trials in the first half of 2027.

Additional considerations include the ongoing litigation with Merck over subcutaneous formulations, which management has described as largely upside, as well as the pace of new collaboration signings and milestone activity. Cost trends also bear watching, as research and development and selling expenses have risen alongside the company's investments in new platforms. For now, the core ENHANZE royalty business continues to compound, but the market's muted reaction to a strong quarter signals that sustaining the stock's momentum may require clear progress on the next generation of growth drivers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations